Thrombosis and Cancer Immunotherapy The Next Frontier of Thromboinflammation Review Abstract Cancer immunotherapy has fundamentally transformed the treatment landscape across multiple malignancies, offering durable responses and prolonged survival in patients with previously limited therapeutic options. Immune checkpoint inhibitors, chimeric antigen receptor T cell therapies, bispecific antibodies,
Tag: immune checkpoint inhibitors
Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC
Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC). Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of
